01
Verified capability
Shanghai Proton and Heavy Ion Center has treated thousands of patients, publishing superior local control in recurrent nasopharyngeal cancer and localized prostate cancer.
Chinese reference name: 复杂或复发肿瘤
Specialized particle radiotherapy (carbon-ion & proton), high-complexity salvage surgery, and indication-specific immunotherapy for recurrent, refractory, or unresectable solid tumors.
Explore Related Clinical Specialties
Begin with Oncology, then compare the support departments that can affect diagnosis, intervention, and recovery planning.
These links organize research only. They do not diagnose, refer, or confirm current case acceptance.
Benchmark your condition, review clinical records needed for triage, and prepare your medical travel plan with leading centers.
Pre-selects Fudan University Shanghai Cancer Center & relevant clinical criteria
Explore clinical indications, treatment modalities, bed and ICU requirements, and patient eligibility criteria verified across leading tertiary centers.
Target Stage & Goal: Local recurrence of nasopharyngeal carcinoma after prior radical photon radiotherapy, or unresectable skull-base chordoma/chondrosarcoma adjacent to critical neurovascular structures.
Siemens synchrotron particle accelerator delivering carbon ions and protons, sub-millimeter 3D pencil-beam scanning, 6-degree-of-freedom robotic treatment couches, real-time 4D CT motion tracking.
Carbon-Ion Re-Irradiation (高相对生物有效性碳离子线二次放疗，精准破坏癌细胞双链DNA且周围危及器官受量急剧下降).
Confirmed localized recurrence or unresectable skull base tumor; interval from previous radiation >1 year; tumor distance to brainstem/optic chiasm >3 mm; KPS performance score ≥70; no distant metastases.
World-renowned head and neck surgical oncology division, high-definition endoscopic skull base surgery theater, multi-modality tumor board.
Transnasal Endoscopic Skull Base Salvage Resection + Intraoperative Navigation.
Resectable recurrence without circumferential internal carotid artery encasement; patient able to tolerate general endotracheal anesthesia.
局部晚期原发性肝癌
Target Stage & Goal: Large solitary or multi-nodular hepatocellular carcinoma not amenable to curative open resection due to insufficient future liver remnant or microvascular invasion.
Advanced respiratory gating system, implanted gold fiducial marker tracking, non-invasive stereotactic body immobilization.
Hypofractionated Carbon-Ion Radiotherapy (大分割碳离子放疗，通常仅需4-10次照射即可彻底消融大体积肝肿瘤).
Child-Pugh class A or well-compensated B (score ≤7); residual non-tumorous liver volume >30%; tumor diameter ≤15 cm; absence of macro-vascular portal vein main trunk occlusion and distant metastases.
World's highest-volume robotic liver resection suites, integrated microvascular interventional catheterization labs (TACE / HAIC), liver transplantation ICU.
Hepatic Arterial Infusion Chemotherapy (HAIC-FOLFOX) downstaging combined with Da Vinci Xi robotic radical liver resection.
BCLC stage B/C liver cancer with good hepatic reserve (ICG-15 <15%); ECOG score 0-1.
局部晚期胰腺癌
Target Stage & Goal: Borderline resectable or locally advanced pancreatic cancer with celiac axis or superior mesenteric artery/vein encasement without distant metastases.
Specialized Pancreatic Cancer Institute, vascular reconstruction surgical theater, carbon-ion beam planning avoiding adjacent duodenal mucosa.
Neoadjuvant Carbon-Ion Radiation / Systemic Chemotherapy followed by Radical Pancreaticoduodenectomy (Whipple) with Mesenteric Vessel Reconstruction.
Pathologically confirmed adenocarcinoma; vascular contact without distant peritoneal seeding; CA19-9 verifiable; KPS score ≥80.
难治复发胶质母细胞瘤与颅内深部肿瘤
Target Stage & Goal: Recurrent glioblastoma or refractory deep brain tumor after standard temozolomide chemoradiation requiring precision re-intervention.
Neurosurgical theaters equipped with intraoperative 3.0T MRI, 5-ALA fluorescence tumor visualization, neuronavigation, proton pencil beam scanning.
Fluorescence-Guided Maximum Safe Microsurgical Resection + Postoperative Focused Carbon-Ion/Proton Particle Boost.
Histologically verified recurrent high-grade glioma (WHO grade 3-4); KPS ≥60; localized recurrence with clear surgical or particle radiotherapy margins.
晚期结直肠癌/胃癌腹膜转移
Target Stage & Goal: Peritoneal surface dissemination from colorectal or gastric cancer with controlled systemic disease and low-to-moderate tumor burden.
Specialized hyperthermic intraperitoneal chemotherapy (HIPEC) closed-loop perfusion machines, 4K 3D laparoscopic surgical theaters.
Cytoreductive Surgery (CRS) + Continuous Hyperthermic Intraperitoneal Chemotherapy (HIPEC) + Targeted Molecular Therapy.
Peritoneal Cancer Index (PCI) score ≤20; complete cytoreduction achievable (CC-0/1); no extra-abdominal metastases; ECOG 0-1.
When This Option May Not Be Suitable
Please evaluate these critical clinical exclusions before initiating cross-border medical consultations.
Documented regulatory approvals, published clinical evidence, and capability standards verified across leading medical centers.
01
Verified capability
Shanghai Proton and Heavy Ion Center has treated thousands of patients, publishing superior local control in recurrent nasopharyngeal cancer and localized prostate cancer.
02
Verified capability
Published clinical cohorts establish feasibility and safety of carbon-ion re-irradiation for head-and-neck and skull base sarcomas.
Hospitals verified for clinical capability, advanced technology access, and international patient coordination pathways.
01
Documented capability
World premier synchrotron delivering both carbon ions and protons with respiratory gating and sub-millimeter robotic tracking.
International access
Official English consultation channel (sphicvip@sphic.org.cn) supporting remote DICOM image prescreening and itemized particle therapy quotes.
Current editorial status
Active international intake. Requires pre-arrival submission of all previous photon radiation dose distribution plans and contrast MRI/PET-CT.
Recurrent nasopharyngeal carcinoma, skull-base chordoma, localized prostate cancer, soft tissue sarcomas
Clinical Feature: High linear energy transfer (LET) heavy particles with sharp Bragg peak; superior cell-killing effect on hypoxic radioresistant tumors.
Pediatric CNS tumors, chordomas, head-and-neck malignancies adjacent to critical neural pathways
Clinical Feature: Zero exit-dose sparing surrounding normal tissue, preserving cognitive and endocrine functions in adjacent structures.
02
Documented capability
National clinical benchmark for comprehensive surgical oncology, pathology consultation, and multidisciplinary tumor board (MDT).
International access
International Medical Department coordinates English record intake, MDT panel review, and priority hospital admission.
Current editorial status
Direct medical intake for international complex-surgery candidates. High surgical complexity threshold.
Locally recurrent nasopharyngeal carcinoma, sinus malignancies, salivary-gland cancers
Clinical Feature: Intraoperative robotic navigation, high-definition endoscope, carotid artery balloon occlusion assessment.
Recurrent pelvic tumors, retroperitoneal liposarcomas, complex colorectal recurrences
Clinical Feature: High-precision nerve-sparing microdissection with multi-organ en-bloc resections.
Contact first, transmit identifiable medical records only through authorized hospital coordination desks.
Having translated clinical records organized accelerates multidisciplinary evaluation and enables accurate treatment feasibility confirmation.
Complete radiation treatment plan reports: Total Gy, fractionation schedule, beam angles, and original DICOM RT dose files
All previous surgical pathology reports, immunohistochemistry (IHC) slides, and molecular genomic testing
Recent high-resolution contrast-enhanced MRI and PET-CT scans performed within 3 weeks (DICOM format)
Documentation of performance status (KPS / ECOG) and neurological deficit exam
Endoscopic reports and photos for head & neck or gastrointestinal lesions
Documented Overall Cost Range & Benchmarks
Standard particle radiotherapy course at Shanghai Proton and Heavy Ion Center is fixed at approximately 278,000 - 310,000 RMB. Surgical oncology pathways range between 150,000 - 350,000 RMB depending on reconstruction complexity.
The fixed particle therapy package does not include preoperative systemic chemotherapy, special custom stents, complex vascular reconstruction, or extended ICU stays.
Scope: Expert radiation oncologist and surgeon review of previous RT dose distributions, DICOM scans, and eligibility confirmation.
Financial Notes: Consultation fee usually paid prior to formal admission; establishes whether carbon-ion or surgery is clinically viable.
Scope: Custom thermoplastic immobilization mask/mold, 4D respiratory-correlated CT, contrast MRI fusion, and physicist beam planning.
Financial Notes: Essential preparatory phase requiring 5-7 days before beam delivery starts.
Scope: Standard course of carbon-ion therapy (typically 12 to 24 fractions) or combined proton boost in specialized treatment gantry.
Financial Notes: SPHIC published standard particle radiotherapy course package is approximately 278,000 - 310,000 RMB for direct radiation.
Scope: Inpatient room charges, mucosal protection, nutritional support, post-treatment verification MRI, and international follow-up schedule.
Financial Notes: Outpatient or inpatient accommodations around the center; total pathway budget should include 30-45 days local stay.
Essential travel considerations, hospital stay durations, and follow-up safety protocols verified for international patients.
Pre-arrival record review, prior-radiation constraints, exclusion criteria, wait time, and itemized international-patient quote Our planning engine benchmarks your medical records, outlines expected cost ranges, and prepares pre-travel intake questions for hospital international desks.
This overview is for medical planning and hospital matching. It does not replace individualized diagnosis by treating specialists. Final treatment plans, drug indications, and quotes must be issued directly by the admitting hospital.